Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs - Summary - MDSpire
Commentary & Perspectives

Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published ...

  • By

  • Lisa Astor

  • April 24, 2026

  • 9 min

Share

Research highlights inconsistencies in reporting venous and arterial thrombotic events in cancer clinical trials, underscoring the need for mandatory uniform reporting to enhance risk assessment and patient consent. Led by Dr. David C. Calverley, the study emphasizes that accurate data is essential for effective prophylaxis and patient management. Thromboembolic events significantly impact cancer patient mortality and morbidity, as evidenced by a study revealing 13.5% incidence of venous thromboembolism post-chemotherapy. An improved reporting framework is advocated to guide treatment protocols and enhance patient outcomes.

Original Source(s)

Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

  • by Lisa Astor

  • April 24, 2026

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies

  • May 12, 2026

  • 3 min
Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life

Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.

  • by

  • April 27, 2026

  • 5 min
Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard

In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of di...